Advertisement

Deep Learning Model Correctly Predicts Time to Alzheimer’s Disease Conversion

Identifying presymptomatic and early mild cognitive impairment (MCI) fast progressors is a crucial component for designing the next generation of Alzheimer’s disease...

Blood Biomarkers Can Help Identify Treatment-Eligible Patients with Alzheimer’s Disease

Clinical trials continue to assess disease-modifying treatment for Alzheimer’s disease (AD), but should a treatment become available, there are concerns that a...

Alzheimer’s-Related Agitation Negatively Impacts Caregivers’ Personal Health Outcomes

Agitation in Alzheimer’s disease (AD) and dementia is a commonly occurring and distressing symptom and is associated with rapid decline in cognitive...

Pimavanserin Significantly Reduces Risk of Psychosis Relapse in Patients with Dementia-Related Psychosis

Pimavanserin, a selective serotonin inverse agonist/antagonist, is FDA-approved to treat hallucinations and delusions associated with Parkinson’s disease (PD) psychosis. This treatment is...
Advertisement